Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Changes in left ventricular mass during a double-blind study with chlorthalidone and slow-release nifedipine

  • 30 Accesses

  • 49 Citations

Summary

The presence of a possible correlation between changes in left ventricular mass of hypertensive patients and the degree of blood pressure reduction with different antihypertensive drugs has been investigated in 40 outpatients by M-mode echocardiography. Ten of these, with blood pressure in normal limits with different antihypertensive treatment had their therapy changed in chlorthalidone 25 mg/day without any run-in (Group A); other 30 patients, with a previously uncontrolled blood pressure, after a 14 day run-in, were randomly allocated to chlorthalidone 25 mg/day (Group B), slow release nifedipine 20 mg/day (Group C) or placebo (Group D). At the end of the eight week treatment period a further decrease in systolic blood pressure was observed in Group A without changes in ventricular mass; an highly significant decrease in both systolic and diastolic blood pressure was observed in B and C but only patients on chlorthalidone changed their ventricular mass; no change in both blood pressure and ventricular mass was observed on placebo. As changes in ventricular mass are not correlated with blood pressure reduction, we conclude that other, not well defined factors, apart from the decrease in duration and degree of left ventricular systolic wall tension, may be responsable for reversal of left ventricular hypertrophy.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Sokolow M, Perloff D (1961) The prognosis of essential hypertension treated conservatively. Circulation 23: 697–713

  2. 2.

    Alcocer L, Aspe J (1979) The effect of antihypertensive treatment with methyldopa on left ventricular mass. In: Robertson JIS, Caldwell ADS (eds) Left ventricular hypertrophy in hypertension. Grune & Stratton, New York, p 94

  3. 3.

    Reichek M, Franklin BB, Chandler T, Muhamad A, Plappert T, St John Sutton M (1982) Reversal of left ventricular hypertrophy by antihypertensive therapy. Eur Heart J [Suppl A]: 165–169

  4. 4.

    Fouad FM, Nakashima Y, Tarazi RC, Salcedo EE (1982) Reversal of left ventricular hypertrophy with methyldopa. Am J Cardiol 49: 795–801

  5. 5.

    Ibrahim MM, Madkour MA, Mossallam R (1980) Effect of atenolol on left ventricular function on hypertensive patients. Circulation 62: 1036–1046

  6. 6.

    Hill LS, Monaghan M, Richardson PJ (1979) Regression of left ventricular hypertrophy during treatment with antihypertensive agents. Br J Clin Pharmacol 7 [Suppl 2]: 255–259

  7. 7.

    Drayer JIM, Gardin JM, Weber MA, Aronow WS (1982) Changes in left ventricular septal thickness during diuretic therapy. Clin Pharmacol Ther 32: 283–288

  8. 8.

    Ferrara LA, de Simone G, Pasanisi F, Mancini Marcello, Mancini M (1984) Left ventricular mass reduction during salt depletion in arterial hypertension. Hypertension 6 (in press)

  9. 9.

    Ostman I, Sjostrand NO, Swedin G (1972) Cardiac noradrenaline turnover and urinary catecholamines excretion in trained and untrained rats during rest and exercise. Acta Physiol Scand 86: 299–308

  10. 10.

    Gans JH, Cater MR (1970) Norepinephrine induced cardiac hypertrophy in dogs. Life Sci 9: 731–734

  11. 11.

    Laks MM, Morady F, Swant HJC (1973) Myocardial hypertrophy produced by chronic infusion of subhypertensive doses of norepinephrine in the dog. Chest 64: 75–78

  12. 12.

    Ostman-Smith I (1981) Cardiac Sympathetic nerves as the final pathway in the induction of cardiac hypertrophy. Clin Sci 61: 265–272

  13. 13.

    Womble JR, Haddox MK, Russel DH (1978) Epinephrine elevation in plasma parallels canine cardiac hypertrophy. Life Sci 23: 1951–1958

  14. 14.

    Ostman-Smith I (1976) Prevention of exercise-induced cardiac hypertrophy in rats by chemical sympathectomy (guanethidine treatment). Neuroscience 1: 497–507

  15. 15.

    Yamori Y, Tarazi RC, Ooshima A (1980) Effect of beta-receptor blocking agents on cardiovascular structural changes in spontaneous and noradrenaline induced hypertension in rats. Clin Sci 59: 457s

  16. 16.

    Tarazi RC, Sen S, Saragoga M, Khairallah P (1982) The multifactorial role of catecholamines in hypertensive cardiac hypertrophy. Eur Heart J 3 [Suppl A]: 103–110

  17. 17.

    Caldarera CM, Casti A, Rossoni C, Visioli O (1971) Polyamines and noradrenaline following myocardial hypertrophy. J Mol Cell Cardiol 3: 121–126

  18. 18.

    Caldarera CM, Orlandini G, Casti A, Moruzzi G (1974) Polyamines and nucleic acid metabolism in myocardial hypertrophy of the overloaded heart. J Mol Cell Cardiol 6: 95–104

  19. 19.

    Weissler AM, Harris WB, Schoenfeld CD (1968) Systolic time intervals in heart failure in man. Circulation 37: 149–159

  20. 20.

    Lewis RP, Rittgers SE, Forester WF, Boudoulas H (1977) A critical review of systolic time intervals. Circulation 56: 146–158

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ferrara, L.A., de Simone, G., Mancini, M. et al. Changes in left ventricular mass during a double-blind study with chlorthalidone and slow-release nifedipine. Eur J Clin Pharmacol 27, 525–528 (1984). https://doi.org/10.1007/BF00556886

Download citation

Key words

  • chlorthalidone
  • nifedipine
  • left ventricular mass
  • slow-release nifedipine